Phosphatidylcholine / Deoxycholate (Lipolytic Injection)

Also known as: PCDC, PC/DC, lipo-dissolve, related to deoxycholic acid (ATX-101/Kybella)

Weight Management

In plain English

This is an injection placed directly into small pockets of fat to try to dissolve fat cells locally (sometimes called "fat-dissolving" or lipo-dissolve). The best evidence for this idea comes from deoxycholic acid alone, which is FDA-approved as Kybella to reduce fat under the chin. The phosphatidylcholine-plus-deoxycholate combination used in compounding is a different, non-FDA-approved formulation, and controlled evidence for it is weaker. Expect local swelling, bruising, and soreness; incorrect placement can injure nearby tissues or nerves.

The science

Deoxycholic acid is a bile acid that disrupts adipocyte cell membranes, causing localized adipocytolysis followed by an inflammatory clearance response. As the single agent ATX-101, it is FDA-approved (Kybella/Belkyra) for submental fat, supported by the randomized, double-blind, placebo-controlled REFINE-1/REFINE-2 phase 3 trials. Compounded phosphatidylcholine/deoxycholate (PCDC) mixtures predate and differ from the purified single-agent product; rigorous randomized evidence for the combination is limited, and only the deoxycholic-acid-alone formulation is FDA-approved. Local adverse effects (swelling, bruising, pain, numbness) are common; off-target injection can cause tissue or nerve injury.

References

• Jones DH et al., Dermatol Surg 2016 (REFINE-1, deoxycholic acid)
• Ascher B et al., J Eur Acad Dermatol Venereol 2014 (phase 3 deoxycholic acid)